OrganiGram Holdings

OrganiGram Holdings earns a Neutral rating with a 42.7 composite and low 2/5 conviction. Regulatory is the strongest pillar at 58, narrowly ahead of fundamentals at 57, while editorial at 30 and market at 15 constrain the overall band. Regulatory strength reflects Canada’s 80 jurisdiction-posture score and an 80 enforcement score, supported by zero enforcement hits. Fundamentals receive their largest contribution from the 90 cash-runway subscore, reflecting positive EBITDA, but the stretched financial condition and continuing net loss prevent that indicator from carrying the rating higher. Weak liquidity and no recent CIN newsroom coverage provide no offset.

Revenue declined 8.9% year over year, limiting the revenue-growth subscore to 41.1. Gross margin was 35.6%, supporting a 59.4 subscore, while the negative 16.4% operating margin produced a comparatively stronger 64.3 subscore within the model’s framework. EBITDA remained positive at approximately $3.0 million, yet net income was a loss of roughly $25.2 million, leaving the financial profile stretched despite positive EBITDA. Market capitalization stood near $136.1 million, corresponding to a 45.3 size-tier subscore. Primary regulatory filings show no events during the latest 90-day period and two during the latest 180-day period, with the latest filing dated May 12, 2026; that cadence translates into a weak 25 subscore. Institutional pricing feeds show zero volume, while CIN newsroom coverage records no newsroom or brief hits. Licensed fundamentals data support the profitability and growth assessment.

The clearest forward catalyst sits within the regulatory pillar, already OrganiGram’s strongest contributor. More consistent primary regulatory filings would directly address the weak cadence component while preserving the favorable jurisdiction and enforcement drivers. That improvement could strengthen confidence in disclosure continuity, but it would not erase the operating loss, revenue contraction, thin market activity, or stretched financial condition. The single most important signal to watch is the arrival of a new primary regulatory filing that improves the current cadence profile.